| Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa L Tshilolo, G Tomlinson, TN Williams, B Santos, P Olupot-Olupot, A Lane, ... New England Journal of Medicine 380 (2), 121-131, 2019 | 271 | 2019 |
| Hydroxyurea therapy for sickle cell anemia PT McGann, RE Ware Expert opinion on drug safety 14 (11), 1749-1758, 2015 | 262 | 2015 |
| Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? PT McGann, RE Ware Current opinion in hematology 18 (3), 158-165, 2011 | 192 | 2011 |
| When actions speak louder than words—racism and sickle cell disease A Power-Hays, PT McGann New England Journal of Medicine 383 (20), 1902-1903, 2020 | 171 | 2020 |
| A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola PT McGann, MG Ferris, U Ramamurthy, B Santos, V de Oliveira, ... American journal of hematology 88 (12), 984-989, 2013 | 125 | 2013 |
| The effects of armed conflict on children A Kadir, S Shenoda, J Goldhagen, S Pitterman, PS Suchdev, KJ Chan, ... Pediatrics 142 (6), 2018 | 103 | 2018 |
| Global human trafficking and child victimization J Greenbaum, N Bodrick, EG Flaherty, SM Idzerda, A Laskey, LA Legano, ... Pediatrics 140 (6), 2017 | 102 | 2017 |
| Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research PT McGann, AG Hernandez, RE Ware Blood, The Journal of the American Society of Hematology 129 (2), 155-161, 2017 | 95 | 2017 |
| Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis O Niss, S Chonat, N Dagaonkar, MO Almansoori, K Kerr, ZR Rogers, ... Blood Cells, Molecules, and Diseases 61, 4-9, 2016 | 74 | 2016 |
| Characteristics of a rapid, point‐of‐care lateral flow immunoassay for the diagnosis of sickle cell disease PT McGann, BA Schaefer, M Paniagua, TA Howard, RE Ware American journal of hematology 91 (2), 205-210, 2016 | 73 | 2016 |
| Current management of sickle cell anemia PT McGann, AC Nero, RE Ware Cold Spring Harbor Perspectives in Medicine 3 (8), a011817, 2013 | 69 | 2013 |
| The effects of armed conflict on children S Shenoda, A Kadir, S Pitterman, J Goldhagen, PS Suchdev, KJ Chan, ... Pediatrics 142 (6), 2018 | 68 | 2018 |
| The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies PT McGann, C Hoppe Blood Cells, Molecules, and Diseases 67, 104-113, 2017 | 66 | 2017 |
| Hydroxyurea therapy for children with sickle cell anemia in sub‐saharan africa: rationale and design of the REACH trial PT McGann, L Tshilolo, B Santos, GA Tomlinson, S Stuber, T Latham, ... Pediatric Blood & Cancer 63 (1), 98-104, 2016 | 64 | 2016 |
| A cost-effectiveness analysis of a pilot neonatal screening program for sickle cell anemia in the Republic of Angola PT McGann, SD Grosse, B Santos, V de Oliveira, L Bernardino, ... The Journal of pediatrics 167 (6), 1314-1319, 2015 | 64 | 2015 |
| Sickle cell anemia: an underappreciated and unaddressed contributor to global childhood mortality PT McGann The Journal of Pediatrics 165 (1), 18-22, 2014 | 62 | 2014 |
| Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia PT McGann, O Niss, M Dong, A Marahatta, TA Howard, T Mizuno, A Lane, ... American journal of hematology 94 (8), 871-879, 2019 | 59 | 2019 |
| Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY‐HUG Phase III Clinical Trial PT McGann, JM Flanagan, TA Howard, SD Dertinger, J He, AS Kulharya, ... Pediatric blood & cancer 59 (2), 254-257, 2012 | 50 | 2012 |
| Time to invest in sickle cell anemia as a global health priority PT McGann Pediatrics 137 (6), 2016 | 49 | 2016 |
| Development of a pharmacokinetic‐guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia M Dong, PT McGann, T Mizuno, RE Ware, AA Vinks British journal of clinical pharmacology 81 (4), 742-752, 2016 | 46 | 2016 |
